The Impact of Angiotensin‐Modulating Antihypertensives on Time Interval to Revision Surgery for Nasal Polyps

Brook, Christopher; Maxfield, Alice Z.; Stanković, Konstantina M.; Metson, Ralph

doi:10.1177/0194599816663924

Cited by 11 publications

(20 citation statements)

References 35 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, given primarily for their antihypertensive and cardioprotective effects, have been shown to reduce expression of periostin and have been linked to delayed polyp regrowth. 17,19,28 We hypothesize that these observed effects reflect inhibition of periostin production by these agents, which may lead to the slowing of polyp formation. Other potential biomarkers and therapeutic targets have been described for CRS, including p-glycoprotein targeted by verapamil, 29 cysteinyl leukotriene targeted by leukotriene receptor antagonists, 30 circulating IgE targeted by omalizumab, 31 and IL-5 targeted by mepolizumab.…”

Section: Discussionmentioning

confidence: 96%

“…18 In a recent study by Brook et al, we found that the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with nasal polyps and asthma significantly delayed the time to revision sinus surgery by >2 years, suggesting a possible mechanism by which polyp formation can be influenced through inhibition of periostin expression. 19 Given these findings, we sought to explore the role of periostin expression in the development of nasal polyps. The purpose of the current study was to measure serum periostin levels in patients with sinonasal disease and controls to determine the applicability of periostin as a potential molecular biomarker for CRS and its endotypes.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis

Maxfield

Landegger

Brook

et al. 2017

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

Objective Periostin is an extracellular matrix protein that is elevated in the sinonasal tissues of patients with chronic rhinosinusitis (CRS). The purpose of this study was to determine whether serum periostin could serve as a molecular biomarker of nasal polyp burden in sinonasal disease. Study Design Prospective cohort study. Setting Academic medical center. Subjects and Methods Serum periostin levels were measured by ELISA on blood samples collected from patients undergoing sinus surgery for CRS (n = 71), further stratified by phenotype as defined by nasal polyps and asthma. Results were compared with assays performed on control subjects (n = 62). Results Mean serum periostin levels were markedly elevated in patients with CRS versus controls (66.1 ng/mL [95% CI, 51.6-80.6] vs 38.7 ng/mL [95% CI, 34.4-42.9], respectively, P = .004). In addition, mean periostin levels were significantly higher in CRS patients with nasal polyps as compared with those without polyps (94.8 ng/mL [95% CI, 67.3-122.4] vs 41.1 ng/mL [95% CI, 35.2-47.0], respectively, P < .001). Periostin levels did not correlate with sex ( P = .473), smoking history ( P = .748), aspirin-exacerbated respiratory disease status ( P = .136), oral steroid use within 1 month of surgery ( P = .281), use of topical steroid nasal spray ( P = .864), or number of prior sinus operations ( P = .973). Conclusion Serum periostin appears to be a novel molecular biomarker for the presence of nasal polyps and may serve as an indicator of CRS endotypes.

show abstract

Section: Discussionmentioning

confidence: 96%

mentioning

confidence: 99%

Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis

Maxfield

Landegger

Brook

et al. 2017

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additional potential MMP modulators may include simvastatin (in vitro studies) (72) , angiotensin converting enzyme inhibitors and angiotensin receptor blockers (case series) (73) .…”

Section: Pharmaceutical Agentsmentioning

confidence: 99%

Matrix metalloproteinases and chronic rhinosinusitis with nasal polyposis. Unravelling a puzzle through a systematic review

Lygeros

Danielides

Grafanaki

et al. 2021

Rhin

View full text Add to dashboard Cite

BACKGROUND: The expression of metalloproteinases (MMPs) in chronic rhinosinusitis with nasal polyposis (CRSwNP) was reviewed in order to investigate their possible use as therapeutical targets and/or biomarkers. METHODOLOGY: The differences between CRSwNP and normal controls or CRS without NP, as well as the effects of various treatments on MMPs, tissue inhibitors of MMPs (TIMPs) and MMP/TIMP ratios were considered as primary outcomes. Additional factors reported to affect MMP expression levels were noted as secondary outcomes. Data regarding inflammatory subtypes, patients’ clinical characteristics, controls, laboratory method(s) and origin of samples were also pooled. Studies on 10 or fewer patients or on specimens other than nasal and serum were excluded. RESULTS: Forty-three studies were included. Tissue sample origin, allergic rhinitis, smoking, infection, medication intake and primary or recurrent disease should be considered as confounding factors for MMP levels. MMP-1 and -7 were consistently found to be significantly higher in CRSwNP patients than controls. CRSwNP endotypes with distinctly different inflammation patterns seem to present similar MMP-related remodelling patterns. CONCLUSIONS: The existing literature has revealed several population and methodology related confounding factors and remains inconclusive regarding the roles of MMPs in CRSwNP pathophysiology and their possible clinical usefulness as biomarkers and therapeutical targets.

show abstract

“…Diagnostic tests for human immunodeficiency virus (HIV), tuberculosis, syphilis and hepatitis should be considered in patients with high-risk exposure to infectious diseases. Th2-type asthma (66)(67)(68) . Serum periostin levels also appear to be higher in patients with NSAID intolerance than in those without it (67) .…”

Section: Infectious Conditionsmentioning

confidence: 99%

European position paper on diagnostic tools in rhinology

Rimmer

Hellings

Lund

et al. 2019

Rhin

114

View full text Add to dashboard Cite

is the official Journal of the European and International Rhinologic Societies and appears quarterly in March, June, September and December. Cited in Pubmed, Current Contents, Index Medicus, Exerpta Medica and Embase Founded in 1963 by H.A.E. van Dishoeck, Rhinology is a worldwide non-profit making journal. The journal publishes original papers on basic research as well as clinical studies in the major field of rhinology, including physiology, diagnostics, pathology, immunology, medical therapy and surgery of both the nose and paranasal sinuses. Review articles and short communications are also pulished. All papers are peer-reviewed. Letters-to-the-editor provide a forum for comments on published papers, and are not subject to editorial revision except for correction of English language. In-depth studies that are too long to be included into a regular issue can be published as a supplement. Supple ments are not subject to peer-review.

show abstract

The Impact of Angiotensin‐Modulating Antihypertensives on Time Interval to Revision Surgery for Nasal Polyps

Abstract: Use of ACEIs and ARBs is associated with an increased time to revision sinus surgery among patients with concurrent nasal polyps and asthma. A possible mechanism of this observed effect is suppression of periostin expression through inhibition of the angiotensin pathway.

Cited by 11 publications

References 35 publications

Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis

Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis

Matrix metalloproteinases and chronic rhinosinusitis with nasal polyposis. Unravelling a puzzle through a systematic review

European position paper on diagnostic tools in rhinology

Contact Info

Product

Resources

About